Lenalidomide (initially known as CC-5013 and marketed as Revlimid® by Celgene) is a derivative of thalidomide introduced in 2004. It was initially intended as a treatment for multiple myeloma, for which thalidomide is an accepted therapeutic modality, but has also shown efficacy in the hematological disorders known as the myelodysplastic syndromes.
See more at Wikipedia.org...
A substance that is being studied in the treatment of cancer. It is similar to thalidomide. It belongs to the family of drugs called angiogenesis inhibitors. Also called CC-5013.
Free Download Now!
